The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $22,102,074 in first-year total cost, median $946,510.
Most frequent study sections
- Special Emphasis Panel[ZCA1 GRB-I (M1)]24
Most frequent institutions
- DANA-FARBER CANCER INST2
- HARVARD SCHOOL OF PUBLIC HEALTH2
- ROCKEFELLER UNIVERSITY2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Targeting intratumor heterogeneity in breast cancer2R35CA197623-08 | POLYAK, KORNELIA | DANA-FARBER CANCER INST, MA | $1,060,812 | ZCA1 |
| 2022 | Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation1R35CA263817-01A1 | GHOBRIAL, IRENE M. | DANA-FARBER CANCER INST, MA | $1,059,900 | ZCA1 |
| 2022 | Modeling and analytics for cancer diagnostics: traversing the data-evidence divide1R35CA274442-01 | ETZIONI, RUTH D | FRED HUTCHINSON CANCER CENTER, WA | $1,055,646 | ZCA1 |
| 2022 | Stalled replication fork repair in cancer predisposition and cancertherapy1R35CA263813-01A1 | SCULLY, RALPH | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $1,022,022 | ZCA1 |
| 2022 | Molecular mechanisms of antibody-mediated immunotherapies2R35CA196620-08 | RAVETCH, JEFFREY VICTOR | ROCKEFELLER UNIVERSITY, NY | $1,017,000 | ZCA1 |
| 2022 | Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study)2R35CA197730-08 | PRIGERSON, HOLLY GWEN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,016,491 | ZCA1 |
| 2022 | Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level2R35CA197745-08 | CALIFANO, ANDREA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $987,000 | ZCA1 |
| 2022 | Interaction between nuclear epigenetic and metabolic pathways in cancer1R35CA263922-01A1 | BERGER, SHELLEY L | UNIVERSITY OF PENNSYLVANIA, PA | $975,000 | ZCA1 |
| 2022 | Decoding and Targeting the PI3K-mTOR Signaling Network in Cancer2R35CA197459-08 | MANNING, BRENDAN D. | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $974,587 | ZCA1 |
| 2022 | Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis2R35CA197591-08 | ATTARDI, LAURA D | STANFORD UNIVERSITY, CA | $955,710 | ZCA1 |
| 2022 | Advancing Cancer Therapy through Groundbreaking Research in Radiation Biology2R35CA197616-08 | KIRSCH, DAVID GUY | DUKE UNIVERSITY, NC | $950,637 | ZCA1 |
| 2022 | Live-cell Activity Architecture in Cancer2R35CA197622-08A1 | ZHANG, JIN | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $948,000 | ZCA1 |
| 2022 | Mutations of Chromatin and its Modifying Machineries in Malignancies2R35CA197569-08A1 | SHILATIFARD, ALI | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $945,019 | ZCA1 |
| 2022 | Molecular Pathogenesis of Acute Myeloid Leukemia2R35CA197561-08 | LEY, TIMOTHY J. | WASHINGTON UNIVERSITY, MO | $944,000 | ZCA1 |
| 2022 | Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer Research2R35CA197449-08 | LIN, XIHONG | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $939,361 | ZCA1 |
| 2022 | Next Generation Cancer Immunotherapies to Defeat Melanoma2R35CA197633-08 | RIBAS, ANTONI | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $936,000 | ZCA1 |
| 2022 | Tackling Undruggable Cancer Targets using Chemoproteomic Platforms1R35CA263814-01A1 | NOMURA, DANIEL | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $928,230 | ZCA1 |
| 2022 | Regulated cell death and responses to starvation in cancer1R35CA263846-01A1 | OVERHOLTZER, MICHAEL H. | SLOAN-KETTERING INST CAN RESEARCH, NY | $920,209 | ZCA1 |
| 2022 | Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities2R35CA197589-08 | CREWS, CRAIG M | YALE UNIVERSITY, CT | $893,050 | ZCA1 |
| 2022 | Studying factors controlling cancer progression and immune recognition in mouse models1R35CA274464-01 | JACKS, TYLER E. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $871,800 | ZCA1 |
| 2022 | Leveraging the National Cancer Institute’s Cancer Center Cessation Initiative (C3I) Program to Evaluate and Transform Smoking Cessation Treatment in Cancer Care2R35CA197573-08 | FIORE, MICHAEL C | UNIVERSITY OF WISCONSIN-MADISON, WI | $861,937 | ZCA1 |
| 2022 | Biology and genetics of metastatic disease1R35CA274446-01 | TAVAZOIE, SOHAIL F. | ROCKEFELLER UNIVERSITY, NY | $709,351 | ZCA1 |
| 2022 | Exploring DNA damage response pathways as targets for cancer therapy1R35CA274234-01 | CHEN, JUNJIE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $583,430 | ZCA1 |
| 2022 | Biology and Function of Exosomes in Cancer1R35CA263815-01A1 | KALLURI, RAGHU | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $546,882 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.